Cipla to acquire 33 percent stake in Clean Max Auriga Power
Mumbai: Cipla Limited has announced that the company has acquired up to 33% of partnership interest in Clean Max Auriga Power LLP (Limited Liability Partnership).
This agreement is in line with the Company's commitment to enhance the share of renewable power source in its operation and to comply with regulatory requirement for being a captive user under electricity laws.
Clean Max Auriga Power LLP is a special purpose vehicle engaged in the business of production, supply and distribution of solar and wind or other renewable energy generation plant. The Company was incorporated on 18th February 2019 and was formed for the purpose of setting up captive wind and solar, renewable power generation plant (Project) in Karnataka.
Mr. Kedar Upadhye, President & Global CFO, Cipla, said, "ESG is at the centre of focus at Cipla and with this acquisition we are progressing on the right track of being purposeful by embedding sustainability into our businesses. It is a testament to our commitment of using cleaner, renewable sources of energy and it fuels our ambition of enabling a greener environment"
Commenting on the development, Ms. Geena Malhotra, Global Chief Technology Officer who spearheads Cipla's ESG agenda said, "This acquisition is in line with our steady efforts towards progressing on goals that we have set out to achieve in the ESG space. Sustainability is at the core of Cipla and while we have miles to go in this path that we have undertaken to achieve our ESG goals, we are gradually moving towards it through such acquisitions and partnerships."
Read also: Cipla to give nebulisers to primary health care centres in India
Cipla Limited is an Indian multinational pharmaceutical and biotechnology company, headquartered in Mumbai, India. The Company was founded by Khwaja Abdul Hamied in 1935 in Mumbai.
Cipla primarily develops medicines to treat respiratory, cardiovascular disease, arthritis, diabetes, weight control, depression, and other medical conditions.
Read also: Cipla launches Spirofy for early diagnosis for COPD
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.